May 9th 2025
Physician groups under 2-sided risk–based Medicare Advantage provide care associated with higher quality and efficiency compared with care by these same groups under fee-for-service Medicare.
CDI-Related Mortality Risk Greater in Hospitalized Children With Cystic Fibrosis
November 11th 2022Pediatric patients who developed coexisting Clostridioides difficile infection (CDI) while hospitalized for cystic fibrosis exhibited greater mortality risk, length of stay, and cost compared with those without cooccuring CDI.
Read More
Dr Liz Lightstone on Emerging Treatment Options, Unmet Needs in Lupus Nephritis
November 11th 2022Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the faculty of medicine, Imperial College London, discussed recently approved therapeutic options for patients with lupus nephritis and what unmet needs persist in the management of the disease.
Watch
Social Impact of Hidradenitis Suppurativa Associated With Worse QOL, Mental Health Burden
November 11th 2022Patients with hidradenitis suppurativa who reported feelings of stigmatization due to their condition had worse quality of life and higher levels of depression and social anxiety vs those not reporting feelings of stigmatization.
Read More
More than 100 health care organizations signed a HHS climate resilience pledge; linking patients in addiction treatment with a primary care practitioner is linked with improved long-term health outcomes; older men and women with weak grip strength may have accelerated biological aging.
Read More
Simvastatin Ineffective as Disease-Modifying Therapy for Intermediate Parkinson Disease
November 10th 2022Patients with intermediate and mild Parkinson disease, defined by a Hoehn & Yahr stage of 3 or less, experienced an additional deterioration in motor function with simvastatin compared with placebo while not taking medication at 24 months.
Read More
What We’re Reading: Listeria Outbreak; COVID-19 Death Decline; Eli Lilly Pays in Drug Patent Trial
November 10th 2022A listeria outbreak has been linked to deli meats and cheeses; the World Health Organization announced that there has been a 90% drop in recent deaths in COVID-19 globally compared with 9 months ago; Eli Lilly was ordered to pay $176.5 million in a US migraine drug patent trial.
Read More
Comorbid Septic Shock, HFrEF Linked to Lack of Guideline-Recommended Treatment
November 10th 2022Patients with heart failure frequently suffer from fluid overload, and for those with heart failure with reduced ejection fraction (HFrEF) also suffering from septic shock—a condition often treated with fluids—more data are needed on outcomes following fluid administration.
Read More
Investigating Real-World Effectiveness of Disease-Modifying Therapies in AD by Skin Type
November 10th 2022Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.
Read More
Examining Risk Factors, Prodromal Features of Parkinson Disease
November 9th 2022Several known risk factors and prodromal features were associated with Parkinson disease, including traumatic brain injury and alcohol misuse, along with other comorbidities such as skin and gastrointestinal disorders.
Read More
Phase 3 Study Shows Live Biotherapeutic Significantly Reduces CDI Recurrence
November 8th 2022A phase 3 study showed Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, to be safe and significantly reduce recurrence of Clostridioides difficile infection (CDI) after antibiotic treatment, with a sustained response achieved through 6 months.
Read More
The Department of Veterans Affairs (VA) will give cancer claims priority when a new law takes effect in January 2023; Pfizer is looking to use its COVID-19 profits to grow other blockbusters; the probable loss of Medicaid coverage for millions next year is setting off debate.
Read More
Poor Self-rated Mental Health and Medicare Beneficiaries’ Routine Care-Seeking
Efforts are needed to ensure that Medicare beneficiaries with poor mental health receive regular routine care, which may be facilitated by having a personal doctor.
Read More
Daniel E. Weiner, MD, MS, board certified nephrologist and lead navigator at Tufts Clinical and Translational Science Institute, spoke on the limitations and future potential of value-based payment systems for chronic kidney disease (CKD), including the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model and the Kidney Care Choices (KCC) Models.
Watch
Curtis Warfield, MS, senior quality analyst, Indiana State Department of Health, and regional leader of National Kidney Foundation's Kidney Advocacy Committee, spoke on limitations regarding the current process of educating and managing lifestyle interventions for patients with chronic kidney disease (CKD), and how nephrologists can better integrate these strategies.
Watch
Nephrology Director Shares Ups, Downs of Participating in Kidney Care First
November 6th 2022It has been 3 years since new kidney care payment models were announced by HHS, and at a session at Kidney Week 2022, the associate division director of nephrology at the University of Alabama at Birmingham described his organization’s participation in Kidney Care First, one of the value-based care models announced in 2019.
Read More
Jen Gunter, MD, obstetrician and gynecologist, author, and specialist in chronic pain medicine and vulvovaginal disorders, spoke on the change in perspective regarding the medical and scientific community's role in dispelling health care misinformation on social media and in the press.
Watch
Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator, discussed findings of the EMPA-KIDNEY trial presented at Kidney Week 2022, which showed a 28% improvement for patients with chronic kidney disease (CKD) on empagliflozin, whether in reduced mortality from cardiovascular disease or progression of CKD.
Watch
Dr Brent W. Miller on Emerging Technologies in Home Dialysis and Strategies to Improve Uptake
November 4th 2022Brent W. Miller, MD, board certified nephrologist and professor of clinical medicine at Indiana University School of Medicine, discussed new and emerging technologies for at-home hemodialysis and peritoneal dialysis, as well as efforts that have been made to address uptake issues for patients with kidney disease.
Watch
Empagliflozin Cuts Risk of Cardiovascular Death, More Severe CKD by 28%, Study Finds
November 4th 2022Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduced the risk of death or worsening progression of chronic kidney disease (CKD) by 28%, according to results published Friday at Kidney Week 2022.
Read More